Substance P receptor mediated maintenance of chronic inflammation in EAE

Journal of Neuroimmunology

Volumn 180, Issue 1-2, 2006, Pages 117-125

  Reinke, Emily K ^a   Johnson, Matthew J ^a   Ling, Changying ^a   Karman, Jozsef ^a   Lee, JangEun ^a   Weinstock, Joel V ^b   Sandor, Matyas ^a   Fabry, Zsuzsa ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

EAE; MS; Neurokinin; Neuropeptide; SR140333; Substance P

Indexed keywords

GAMMA INTERFERON; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NOLPITANTIUM; SUBSTANCE P RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CHRONIC DISEASE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DRUG EFFECT; ENTERITIS; FEMALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BLOCKING; SYMPTOM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNITY, CELLULAR; IMMUNOSUPPRESSION; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; MYELIN-ASSOCIATED GLYCOPROTEIN; NEUROIMMUNOMODULATION; PIPERIDINES; QUINUCLIDINES; RECEPTORS, NEUROKININ-1; SUBSTANCE P;

EID: 33750610585     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.07.010     Document Type: Article

References (51)

1. Annunziata P., Cioni C., Santonini R., and Paccagnini E. Substance P antagonist blocks leakage and reduces activation of cytokine-stimulated rat brain endothelium. J. Neuroimmunol. 131 (2002) 41-49
2. Arsenescu R., Blum A.M., Metwali A., Elliott D.E., and Weinstock J.V. IL-12 induction of mRNA encoding substance P in murine macrophages from the spleen and sites of inflammation. J. Immunol. 174 (2005) 3906-3911
3. Barker R., and Larner A. Substance P and multiple sclerosis. Med. Hypotheses 37 (1992) 40-43
4. Blum A.M., Metwali A., Cook G., Mathew R.C., Elliott D., and Weinstock J.V. Substance P modulates antigen-induced, IFN-gamma production in murine Schistosomiasis mansoni. J. Immunol. 151 (1993) 225-233
5. Blum A.M., Metwali A., Crawford C., Li J., Qadir K., Elliott D.E., and Weinstock J.V. Interleukin 12 and antigen independently induce substance P receptor expression in T cells in murine Schistosomiasis mansoni. FASEB. J. 15 (2001) 950-957
6. Blum A.M., Metwali A., Elliott D.E., and Weinstock J.V. T cell substance P receptor governs antigen-elicited IFN-gamma production. Am. J. Physiol.: Gasterointest. Liver Physiol. 284 (2003) G197-G204
7. Castagliuolo I., Keates A.C., Qiu B., Kelly C.P., Nikulasson S., Leeman S.E., and Pothoulakis C. Increased substance P responses in dorsal root ganglia and intestinal macrophages during Clostridium difficile toxin A enteritis in rats. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4788-4793
8. Cook G.A., Elliott D., Metwali A., Blum A.M., Sandor M., Lynch R., and Weinstock J.V. Molecular evidence that granuloma T lymphocytes in murine Schistosomiasis mansoni express an authentic substance P (NK-1) receptor. J. Immunol. 152 (1994) 1830-1835
9. Crum N.F., Lederman E.R., and Wallace M.R. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 84 (2005) 291-302
10. Dimri R., Sharabi Y., and Shoham J. Specific inhibition of glucocorticoid-induced thymocyte apoptosis by substance P. J. Immunol. 164 (2000) 2479-2486
11. Elsawa S.F., Taylor W., Petty C.C., Marriott I., Weinstock J.V., and Bost K.L. Reduced CTL response and increased viral burden in substance P receptor-deficient mice infected with murine gamma-herpesvirus 68. J. Immunol. 170 (2003) 2605-2612
12. Emonds-Alt X., Doutremepuich J.D., Heaulme M., Neliat G., Santucci V., Steinberg R., Vilain P., Bichon D., Ducoux J.P., Proietto V., et al. In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonist. Eur. J. Pharmacol. 250 (1993) 403-413
13. Fleming K.K., Bovaird J.A., Mosier M.C., Emerson M.R., LeVine S.M., and Marquis J.G. Statistical analysis of data from studies on experimental autoimmune encephalomyelitis. J. Neuroimmunol. 170 (2005) 71-84
14. Goode T., O'Connell J., Anton P., Wong H., Reeve J., O'Sullivan G.C., Collins J.K., and Shanahan F. Neurokinin-1 receptor expression in inflammatory bowel disease: molecular quantitation and localisation. Gut 47 (2000) 387-396
15. Kart E., Jocham G., Muller C.P., Schlomer C., Brandao M.L., Huston J.P., and de Souza Silva M.A. Neurokinin-1 receptor antagonism by SR140333: enhanced in vivo ACh in the hippocampus and promnestic post-trial effects. Peptides 25 (2004) 1959-1969
16. Kennedy P.G., Rodgers J., Jennings F.W., Murray M., Leeman S.E., and Burke J.M. A substance P antagonist, RP-67,580, ameliorates a mouse meningoencephalitic response to Trypanosoma brucei brucei. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4167-4170
17. Kennedy P.G., Rodgers J., Bradley B., Hunt S.P., Gettinby G., Leeman S.E., de Felipe C., and Murray M. Clinical and neuroinflammatory responses to meningoencephalitis in substance P receptor knockout mice. Brain 126 (2003) 1683-1690
18. Kincy-Cain T., and Bost K.L. Substance P-induced IL-12 production by murine macrophages. J. Immunol. 158 (1997) 2334-2339
19. Kostyk S.K., Kowall N.W., and Hauser S.L. Substance P immunoreactive astrocytes are present in multiple sclerosis plaques. Brain Res. 504 (1989) 284-288
20. Lambert N., Lescoulie P.L., Yassine-Diab B., Enault G., Mazieres B., De Preval C., and Cantagrel A. Substance P enhances cytokine-induced vascular cell adhesion molecule-1 (VCAM-1) expression on cultured rheumatoid fibroblast-like synoviocytes. Clin. Exp. Immunol. 113 (1998) 269-275
21. Lambrecht B.N., Germonpre P.R., Everaert E.G., Carro-Muino I., De Veerman M., de Felipe C., Hunt S.P., Thielemans K., Joos G.F., and Pauwels R.A. Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation. Eur. J. Immunol. 29 (1999) 3815-3825
22. Levite M. Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 12544-12549
23. Lin R.C. Reactive astrocytes express substance-P immunoreactivity in the adult forebrain after injury. Neuroreport 7 (1995) 310-312
24. Mantyh C.R., Gates T.S., Zimmerman R.P., Welton M.L., Passaro E.P., Vigna S.R., Maggio J.E., Kruger L., and Mantyh P.W. Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in high concentrations by arterioles, venules, and lymph nodules in surgical specimens obtained from patients with ulcerative colitis and Crohn disease. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 3235-3239
25. Mantyh P.W., Johnson D.J., Boehmer C.G., Catton M.D., Vinters H.V., Maggio J.E., Too H.P., and Vigna S.R. Substance P receptor binding sites are expressed by glia in vivo after neuronal injury. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 5193-5197
26. Mantyh C.R., Vigna S.R., Maggio J.E., Mantyh P.W., Bollinger R.R., and Pappas T.N. Substance P binding sites on intestinal lymphoid aggregates and blood vessels in inflammatory bowel disease correspond to authentic NK-1 receptors. Neurosci. Lett. 178 (1994) 255-259
27. Mantyh C.R., Vigna S.R., Bollinger R.R., Mantyh P.W., Maggio J.E., and Pappas T.N. Differential expression of substance P receptors in patients with Crohn's disease and ulcerative colitis. Gastroenterology 109 (1995) 850-860
28. Marriott I., and Bost K.L. IL-4 and IFN-gamma up-regulate substance P receptor expression in murine peritoneal macrophages. J. Immunol. 165 (2000) 182-191
29. Menkes C.J., Renoux M., Laoussadi S., Mauborgne A., Bruxelle J., and Cesselin F. Substance P levels in the synovium and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. J. Rheumatol. 20 (1993) 714-717
30. Michaud J.C., Alonso R., Gueudet C., Fournier M., Calassi R., Breliere J.C., Le Fur G., and Soubrie P. Effects of SR140333, a selective non-peptide NK1 receptor antagonist, on trigemino-thalamic nociceptive pathways in the rat. Fundam. Clin. Pharmacol. 12 (1998) 88-94
31. Persson-Sjogren S., Lejon K., Holmberg D., and Forsgren S. Expression of the NK-1 receptor on islet cells and invading immune cells in the non-obese diabetic mouse. J. Autoimmun. 24 (2005) 269-279
32. Pinter E., Than M., Chu D.Q., Fogg C., and Brain S.D. Interaction between interleukin 1beta and endogenous neurokinin 1 receptor agonists in mediating plasma extravasation and neutrophil accumulation in the cutaneous microvasculature of the rat. Neurosci. Lett. 318 (2002) 13-16
33. Powell K.J., Quirion R., and Jhamandas K. Inhibition of neurokinin-1-substance P receptor and prostanoid activity prevents and reverses the development of morphine tolerance in vivo and the morphine-induced increase in CGRP expression in cultured dorsal root ganglion neurons. Eur. J. Neurosci. 18 (2003) 1572-1583
34. Qureshi G.A., Baig S.M., and Parvez S.H. Variation in cerebrospinal fluid levels of neuropeptide Y, cholecystokinin and substance P in patients with neurological disorders. Neuroendocrinol. Lett. 21 (2000) 409-416
35. R-Development-Core-Team. R: A Language and Environment for Statistical Computing (2005) Vienna, Austria
36. Reinke E., and Fabry Z. Breaking or making immunological privilege in the central nervous system: The regulation of immunity by neuropeptides. Immunol. Lett. 104 1-2 (2006) 102-109
37. Rosler N., Reuner C., Geiger J., Rissler K., and Cramer H. Cerebrospinal fluid levels of immunoreactive substance P and somatostatin in patients with multiple sclerosis and inflammatory CNS disease. Peptides 11 (1990) 181-183
38. Rupniak N.M., Carlson E.J., Shepheard S., Bentley G., Williams A.R., Hill A., Swain C., Mills S.G., Di Salvo J., Kilburn R., Cascieri M.A., Kurtz M.M., Tsao K.L., Gould S.L., and Chicchi G.G. Comparison of the functional blockade of rat substance P (NK1) receptors by GR205171, RP67580, SR140333 and NKP-608. Neuropharmacology 45 (2003) 231-241
39. Rupniak N.M., Fisher A., Boyce S., Clarke D., Pike A., O'Connor D., and Watt A. P-Glycoprotein efflux reduces the brain concentration of the substance P (NK1 receptor) antagonists SR140333 and GR205171: a comparative study using mdr1a -/- and mdr1a +/+ mice. Behav. Pharmacol. 14 (2003) 457-463
40. Rychly D.J., and DiPiro J.T. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 25 (2005) 1181-1192
41. Sakai K., Matsuno H., Tsuji H., and Tohyama M. Substance P receptor (NK1) gene expression in synovial tissue in rheumatoid arthritis and osteoarthritis. Scand. J. Rheumatol. 27 (1998) 135-141
42. Santoni G., Amantini C., Lucciarini R., Pompei P., Perfumi M., Nabissi M., Morrone S., and Piccoli M. Expression of substance P and its neurokinin-1 receptor on thymocytes: functional relevance in the regulation of thymocyte apoptosis and proliferation. Neuroimmunomodulation 10 (2002) 232-246
43. Santos J.M., Tatsuo M.A., Turchetti-Maia R.M., Lisboa M.C., and de Francischi J.N. Leukocyte recruitment to peritoneal cavity of rats following formalin injection: role of tachykinin receptors. J. Pharmacol. Sci. 94 (2004) 384-392
44. Schuiling M., Zuidhof A.B., Zaagsma J., and Meurs H. Involvement of tachykinin NK1 receptor in the development of allergen-induced airway hyperreactivity and airway inflammation in conscious, unrestrained guinea pigs. Am. J. Respir. Crit. Care. Med. 159 (1999) 423-430
45. Sekizawa S., Joad J.P., and Bonham A.C. Substance P presynaptically depresses the transmission of sensory input to bronchopulmonary neurons in the guinea pig nucleus Tractus solitarii. J. Physiol. 552 (2003) 547-559
46. Stumm R., Culmsee C., Schafer M.K., Krieglstein J., and Weihe E. Adaptive plasticity in tachykinin and tachykinin receptor expression after focal cerebral ischemia is differentially linked to gabaergic and glutamatergic cerebrocortical circuits and cerebrovenular endothelium. J. Neurosci. 21 (2001) 798-811
47. Sturiale S., Barbara G., Qiu B., Figini M., Geppetti P., Gerard N., Gerard C., Grady E.F., Bunnett N.W., and Collins S.M. Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 11653-11658
48. Tripp R.A., Barskey A., Goss L., and Anderson L.J. Substance P receptor expression on lymphocytes is associated with the immune response to respiratory syncytial virus infection. J. Neuroimmunol. 129 (2002) 141-153
49. Wease K.N., and Davies S.N. Substance P selectively decreases paired pulse depression in the rat hippocampal slice. BMC Neurosci. 6 (2005) 66
50. Weinstock J.V., Blum A., Metwali A., Elliott D., Bunnett N., and Arsenescu R. Substance P regulates Th1-type colitis in IL-10 knockout mice. J. Immunol. 171 (2003) 3762-3767
51. Yu Z., Cheng G., Huang X., Li K., and Cao X. Neurokinin-1 receptor antagonist SR140333: a novel type of drug to treat cerebral ischemia. Neuroreport 8 (1997) 2117-2119